Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2023 Publisher: Milpharm Limited, Ares Block, Odyssey Business Park, West End Road, Ruislip HA4 6QD, United Kingdom
ROPIQUAL XL 2 mg prolonged-release tablets.
| Pharmaceutical Form |
|---|
|
Prolonged-release tablet. 2 mg prolonged-release tablets: pink, round biconvex tablets 6.8 ± 0.1 mm. |
Each prolonged-release tablet contains 2 mg of ropinirole (as hydrochloride).
Excipients with known effect: 1.8 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Ropinirole |
Ropinirole is a non-ergoline D2/D3 dopamine agonist which stimulates striatal dopamine receptors. Ropinirole alleviates the dopamine deficiency which characterises Parkinson’s disease by stimulating striatal dopamine receptors. |
| List of Excipients |
|---|
|
Tablet core: Ammonio Methacrylate Copolymer, Type B Tablet coat: Lactose monohydrate |
ROPIQUAL XL is supplied in white opaque PVC/PCTFE-Aluminum foil blister packs of 28, 30, 42 and 84 tablets.
Not all pack sizes may be marketed.
Milpharm Limited, Ares Block, Odyssey Business Park, West End Road, Ruislip HA4 6QD, United Kingdom
PL 16363/0236
30/07/2021
| Drug | Countries | |
|---|---|---|
| ROPIQUAL | United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
